Suomi - suomi - Fimea (Suomen lääkevirasto)

baxter oy - aspartic acid, glutamic acid, alanine, arginine, calcium chloride dihydrate, glucose monohydrate, aminoacetic acid, histidine, isoleucine, cysteine, leucine, methionine, proline, serine, threonine, tryptophane, tyrosine, valine, sodium chloride, ornithine, taurine, lysine monohydrate, magnesium acetate tetrahydrate, soya-bean oil, refined, olive oil, refined, sodium glycerophosphate hydrate - infuusioneste, emulsio - yhdistelmävalmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - budesonidum,formoteroli fumaras dihydricus - inhalaatiojauhe - 80 mikrog / 4.5 mikrog / inhalaatio - formoteroli ja budesonidi

Euroopan unioni - suomi - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - niveltulehdus, nivelreuma - immunosuppressantit - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Suomi - suomi - Fimea (Suomen lääkevirasto)

abbvie oy - foslevodopa, foscarbidopa - infuusioneste, liuos - 240 mg/ml + 12 mg/ml - dopa ja dopajohdokset

Suomi - suomi - Fimea (Suomen lääkevirasto)

medical valley invest ab - budesonide - säädellysti vapauttava kapseli, kova - 3 mg - budesonidi

Euroopan unioni - suomi - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - migreenihäiriöt - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Euroopan unioni - suomi - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Suomi - suomi - Fimea (Suomen lääkevirasto)

lohmann animal health gmbh - chicken anaemia virus, live - kuiva-aine, kylmäkuivattu, juomaveteen sekoitettavaksi - sinisiipitauti -rokote

Suomi - suomi - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - atomoxetine hydrochloride - kapseli, kova - 10 mg - atomoksetiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

mundipharma oy - hydromorphone hydrochloride - depotkapseli, kova - 4 mg - hydromorfoni